Molecular mechanisms of altered cholesterol metabolism in rats with spontaneous focal glomerulosclerosis Nosratola D. Vaziri, Tadashi Sato, Kaihui Liang

Slides:

Advertisements

Similar presentations

Cholesterol metabolism

Advertisements

Ischemic heart disease after renal transplantation

Schematic overview of the role of LCAT in lipoprotein metabolism

RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone Eduardo A. Slatopolsky, Steven K.

Myoung J. Kang, Alistair Ingram, Hao Ly, Kerri Thai, James W. Scholey

Volume 54, Issue 4, Pages (October 1998)

Lead exposure raises superoxide and hydrogen peroxide in human endothelial and vascular smooth muscle cells Zhenmin Ni, Stephen Hou, Cyril H. Barton,

Transport of lipids Title slide - the transport of lipids. Important because they aren’t water soluble.

Dyslipidemia in chronic kidney disease: Causes and consequences

Cyril H. Barton, Zehnmin Ni, Nosratola D. Vaziri Kidney International

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

Volume 79, Issue 9, Pages (May 2011)

Bettina Haslinger-Löffler Kidney International

Lipopheresis in the nephrotic syndrome

Figure 1 Overview of lipoprotein metabolism and effects of novel lipid-modulating approaches Figure 1 | Overview of lipoprotein metabolism and effects.

Sebelipase alfa improves atherogenic biomarkers in adults and children with lysosomal acid lipase deficiency Don P. Wilson, MD, FNLA, Mark Friedman,

My Approach to the Patient With Familial Hypercholesterolemia

Effects of ethanol on lipids and atherosclerosis

HCV and the hepatic lipid pathway as a potential treatment target

RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone Eduardo A. Slatopolsky, Steven K.

Volume 74, Issue 7, Pages (October 2008)

Eveline Oestreicher Stock, MD, Christine T

Susumu Takahashi, Kazuyoshi Okada, Mitsuru Yanai Kidney International

Volume 59, Issue 1, Pages (January 2001)

Scavenger Receptor B-1 Emerges as Anti-atherogenic Candidate

Volume 54, Issue 1, Pages (July 1998)

Nosratola D. Vaziri, Kaihui Liang, Yaoxian Ding Kidney International

Ian H. de Boer, Rajnish Mehrotra Kidney International

Toward Individualized Cholesterol-Lowering Treatment in End-Stage Renal Disease Guenther Silbernagel, MD, Iris Baumgartner, MD, Christoph Wanner, MD,

Volume 82, Issue 9, Pages (November 2012)

Growth hormone promotes glomerular lipid accumulation in bGH mice

Enlightenment on liver lanthanum exposure

Up-regulation of kidney NAD(P)H oxidase and calcineurin in SHR: Reversal by lifelong antioxidant supplementation Chang-de Zhan, Ram K. Sindhu, Nosratola.

New insights into lipid metabolism in the nephrotic syndrome

Angiotensin-(1–7) inhibits angiotensin II-stimulated phosphorylation of MAP kinases in proximal tubular cells Z. Su, J. Zimpelmann, K.D. Burns Kidney.

Volume 61, Issue 5, Pages (May 2002)

Volume 76, Issue 4, Pages (August 2009)

Nat. Rev. Nephrol. doi: /nrneph

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Volume 62, Issue 3, Pages (September 2002)

Role of endothelin and nitric oxide imbalance in the pathogenesis of hypoxia-induced arterial hypertension Zhenmin Ni, Shahrooz Bemanian, Salah D. Kivlighn,

The future of renoprotection: Frustration and promises

Volume 84, Issue 5, Pages (November 2013)

Volume 87, Issue 1, Pages (January 2015)

Choong Kim, Nosratola D. Vaziri Kidney International

Volume 67, Issue 4, Pages (April 2005)

Volume 56, Pages S70-S75 (July 1999)

Kaihui Liang, Nosratola D. Vaziri Kidney International

Calcium on trial: Beyond a reasonable doubt?

Volume 63, Issue 1, Pages (January 2003)

Volume 54, Issue 4, Pages (October 1998)

Mediterranean diets: are they practical in the Western world?

Nosratola D. Vaziri, M.D., Kaihui Liang Kidney International

Cyril H. Barton, Zhemin Ni, Nosratola D. Vaziri Kidney International

Volume 80, Issue 10, Pages (November 2011)

Volume 80, Issue 10, Pages (November 2011)

Volume 56, Pages S28-S30 (July 1999)

Lipoproteins Macromolecular complexes in the blood that transport lipids Apolipoproteins Proteins on the surface of lipoproteins; they play critical.

Charles A. Herzog Kidney International

Volume 70, Issue 3, Pages (August 2006)

Volume 53, Issue 4, Pages (April 1998)

Volume 70, Issue 5, Pages (September 2006)

Volume 76, Issue 9, Pages (November 2009)

Ischemic heart disease after renal transplantation

Volume 61, Issue 1, Pages (January 2002)

Volume 56, Issue 6, Pages (December 1999)

Role of altered renal lipid metabolism and the sterol regulatory element binding proteins in the pathogenesis of age-related renal disease T.A.O. Jiang,

Role of CETP in plasma cholesterol transport.

Volume 66, Issue 1, Pages (July 2004)

Presentation transcript:

Molecular mechanisms of altered cholesterol metabolism in rats with spontaneous focal glomerulosclerosis Nosratola D. Vaziri, Tadashi Sato, Kaihui Liang Kidney International Volume 63, Issue 5, Pages 1756-1763 (May 2003) DOI: 10.1046/j.1523-1755.2003.00911.x Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 1 Representative Western blot and group data depicting hepatic tissue microsomal 3-hydroxy-3 methyglutaryl coenzyme A (HMG-CoA) reductase protein abundance and plasma cholesterol concentration in the 34-week-old Imai rats with focal glomerulosclerosis (FGS) and the age-matched normal control group.N = 6 in each group. *P < 0.01. Kidney International 2003 63, 1756-1763DOI: (10.1046/j.1523-1755.2003.00911.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 2 Representative Western blot and group data depicting hepatic tissue microsomal cholesterol 7α-hydroxylase (CH-7α) protein abundance and 3-hydroxy-3 methyglutaryl coenzyme A (HMG-CoA) reductase-to-cholesterol 7α-hydroxylase ratio in the 34-week-old Imai rats with focal glomerulosclerosis (FGS) and the age-matched normal control group.N = 6 in each group. No significant difference was found. Kidney International 2003 63, 1756-1763DOI: (10.1046/j.1523-1755.2003.00911.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 3 Representative Western blot and group data depicting hepatic tissue plasma membrane low-density lipoprotein (LDL) receptor protein abundance and plasma LDL concentration in the 34-week-old Imai rats with focal glomerulosclerosis (FGS) and the age-matched normal control group.N = 6 in each group. *P < 0.01. Kidney International 2003 63, 1756-1763DOI: (10.1046/j.1523-1755.2003.00911.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 4 Representative Western blot and group data depicting hepatic tissue acyl CoA:cholesterol acyltransferase (ACAT-2) protein abundance, liver-free cholesterol and plasma very low-density lipoprotein (VLDL) concentration in the 34-week-old Imai rats with focal glomerulosclerosis (FGS) and the age-matched normal control group.N = 6 in each group. *P < 0.01. Kidney International 2003 63, 1756-1763DOI: (10.1046/j.1523-1755.2003.00911.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 5 Plasma lecithin:cholesterol acyltransferase (LCAT) protein concentration plasma-free cholesterol and high-density lipoprotein (LDL) to high-density lipoprotein (HDL) cholesterol ratio in the 34-week-old Imai rats with focal glomerulosclerosis (FGS) and the age-matched normal control group.N = 6 animals in each group. *P < 0.01. Kidney International 2003 63, 1756-1763DOI: (10.1046/j.1523-1755.2003.00911.x) Copyright © 2003 International Society of Nephrology Terms and Conditions